Overview

KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy

Status:
Terminated

Trial end date:
2014-05-01

Target enrollment:

Participant gender:

Summary

This study involves treatment with KD019 or erlotinib in patients with Non-small cell lung cancer (NSCLC) who have progressed after first- or second- line chemotherapy. It is hypothesized that KD019 can prolong survival compared with erlotinib.

Phase:

Phase 3

Details

Lead Sponsor:

Kadmon Corporation, LLC

Treatments:

Erlotinib Hydrochloride